Grants

You have a project that fits the PRIM mission: go to our grant page for the procedure

Read more

Industry

Latest News

2012 May 9th 18h30-20h00 Innovation evening. Presentation of new drug approvals 2011-2012 :

2012 April 18th: Science Day at the Hall of Theses from the University of Lille 1, organized by the Committee of Direction of Prim.

Read More

Consult past events and seminars organized by PRIM :

Read more

New article about PRIM in Le Nouvel Observateur :

Read More

Mailing list

Keep informed on Scientific Meetings and grant filing.
Rester informé sur les manifestations scientifiques et les appels d'offre.

Registration

SCIENCE > Projects

List of the scientific projects that received grants

For equipment grants see Equipments page

  • PRIM-CAIRICOL: Potentialisation of the activity of topoisomerase I inhibitors by carbonic anhydrase IX inhibitors: treatment of colorectal cancers.(2009/-)

    Coordinators:

    • EA4034 : Jean-François Goossens
    • CHR-Oscar Lambret : Amélie Lansiaux

    Mission:

    Potentialisation of the activity of topoisomerase I inhibitors by inhibitors of carbonic anhydrase type IX : applications to the treatment of colorectal cancers.

    Objectives and rationale:

    The limitation of the extracellular acidity using inhibitors of carbonic anhydrase type IX allows better membrane permeation of basic anticancer agents such as the inhibitors of topoisomerase I. This will improve the cytotoxic activity of these compounds. The synthesis and physico-chemical characterization of new carbonic anhydrase IX inhibitors has been successful. This project is done in collaboration with teams from Pr Masereel (University of Namur, Belgium) for molecular modeling and Pr Supuran (University of Florence) for enzymatic assays. The objective of this multidisciplinary project is to develop specific carbonic anhydrase IX inhibitors and to evaluate both in vitro and in vivo the potentialisation of the effects of topoisomerase I inhibitors (derived from campothecin). These compounds will be assayed in colorectal cancer models to achieve this goal.